{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:16:31Z","timestamp":1788376591889,"version":"build-2803163510"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian Government Research Training Program"},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2034282"],"award-info":[{"award-number":["2034282"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["2016491"],"award-info":[{"award-number":["2016491"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1173528"],"award-info":[{"award-number":["1173528"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1173027"],"award-info":[{"award-number":["1173027"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["2033318"],"award-info":[{"award-number":["2033318"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Australian Medical Research Future Fund","award":["2016062"],"award-info":[{"award-number":["2016062"]}]},{"name":"Australian Medical Research Future Fund","award":["2016062"],"award-info":[{"award-number":["2016062"]}]},{"name":"Australian Medical Research Future Fund","award":["2016062"],"award-info":[{"award-number":["2016062"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vaccine-induced neutralising antibodies are a well-established correlate of protection against acquisition of COVID-19. Vaccine protection from severe COVID-19 remains high, although the role of neutralising antibodies and the contribution of other immune responses to protection from severe outcomes is less clear. Improving understanding of how vaccines prevent severe outcomes is important for future vaccine development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      Here we undertake a systematic search of the literature to obtain estimates of vaccine protection against progression from SARS-CoV-2 infection to severe COVID-19 (hospital or ICU admission). We aggregate results from 25 published clinical studies of vaccine protection from progression to severe outcomes in people with SARS-CoV-2 infection. We match this clinical data to data from 301 studies of post-vaccination neutralisation titres induced by various vaccines against different SARS-CoV-2 variants from the publicly available Stanford University Coronavirus antiviral and resistance database. We then synthesise the data using meta-regression. Neutralising antibody titres were found to be associated with vaccine protection against progression to severe COVID-19 (relative risk (RR) 0.57 per 10-fold increase in GMT, 95% CI [0.51,0.64],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). We found that the protection against progression provided by vaccination was higher than that provided by therapeutic passive administration of antibodies, when used to treat individuals with confirmed infection. The main methodological limitations were the fact that neutralisation titres and clinical outcomes were measured in different studies, and the possibility of unmeasured confounding.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Together, this work suggests that vaccine-induced neutralising antibodies are correlated with protection from progression to severe COVID-19 and can account for at least a partial mechanistic role in this protection. However, a protection gap remains between the high levels of protection against progressing to severe COVID-19 afforded by vaccination, compared to that afforded by therapeutic administration of antibodies, suggesting other immune responses may also play a role.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1005230","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:43:27Z","timestamp":1788374607000},"page":"e1005230","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4989-5552","authenticated-orcid":true,"given":"Karen M.","family":"Elias","sequence":"first","affiliation":[{"name":"University of New South Wales","place":["Sydney, Australia"],"department":["Kirby Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainslie","family":"Mitchell","sequence":"additional","affiliation":[{"name":"University of New South Wales","place":["Sydney, Australia"],"department":["Kirby Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5129-8180","authenticated-orcid":true,"given":"Eva","family":"Stadler","sequence":"additional","affiliation":[{"name":"University of New South Wales","place":["Sydney, Australia"],"department":["Kirby Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7746-9649","authenticated-orcid":true,"given":"Timothy E.","family":"Schlub","sequence":"additional","affiliation":[{"name":"University of New South Wales","place":["Sydney, Australia"],"department":["Kirby Institute"]},{"name":"University of Sydney","place":["Sydney, New South Wales, Australia"],"department":["Faculty of Medicine and Health, Sydney School of Public Health"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-6122","authenticated-orcid":true,"given":"Shanchita R.","family":"Khan","sequence":"additional","affiliation":[{"name":"University of New South Wales","place":["Sydney, Australia"],"department":["Kirby Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0870-6668","authenticated-orcid":true,"given":"Claire","family":"Xue","sequence":"additional","affiliation":[{"name":"School of Mathematics and Statistics, University of New South Wales","place":["Sydney, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-4891","authenticated-orcid":true,"given":"Stephen J.","family":"Kent","sequence":"additional","affiliation":[{"name":"University of Melbourne at the Peter Doherty Institute for Infection and Immunity","place":["Melbourne, Victoria, Australia"],"department":["Department of Microbiology and Immunology"]},{"name":"Alfred Hospital and Central Clinical School, Monash University","place":["Melbourne, Victoria, Australia"],"department":["Melbourne Sexual Health Centre and Department of Infectious Diseases"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-5094","authenticated-orcid":true,"given":"Deborah","family":"Cromer","sequence":"additional","affiliation":[{"name":"University of New South Wales","place":["Sydney, Australia"],"department":["Kirby Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-1831","authenticated-orcid":true,"given":"Miles P.","family":"Davenport","sequence":"additional","affiliation":[{"name":"University of New South Wales","place":["Sydney, Australia"],"department":["Kirby Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-1551","authenticated-orcid":true,"given":"David S.","family":"Khoury","sequence":"additional","affiliation":[{"name":"University of New South Wales","place":["Sydney, Australia"],"department":["Kirby Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"32","key":"pmed.1005230.ref001","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"KA Earle","year":"2021","journal-title":"Vaccine"},{"issue":"12","key":"pmed.1005230.ref002","article-title":"Efficacy and safety of COVID\u201019 vaccines","author":"C Gra\u00f1a","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"pmed.1005230.ref003","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"DS Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"pmed.1005230.ref004","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41577-022-00716-1","article-title":"Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?","volume":"22","author":"SJ Kent","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"724","key":"pmed.1005230.ref005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh4529","article-title":"T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19","volume":"15","author":"R Zonozi","year":"2023","journal-title":"Sci Transl Med"},{"issue":"11","key":"pmed.1005230.ref006","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"S Feng","year":"2021","journal-title":"Nat Med"},{"issue":"6576","key":"pmed.1005230.ref007","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"PB Gilbert","year":"2022","journal-title":"Science"},{"issue":"1","key":"pmed.1005230.ref008","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41467-023-40204-1","article-title":"Monoclonal antibody levels and protection from COVID-19","volume":"14","author":"E Stadler","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"pmed.1005230.ref009","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1038\/s41467-023-39292-w","article-title":"Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration","volume":"14","author":"D Follmann","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"pmed.1005230.ref010","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/s41467-023-37176-7","article-title":"Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis","volume":"14","author":"D Cromer","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"pmed.1005230.ref011","doi-asserted-by":"crossref","first-page":"9785","DOI":"10.1038\/s41467-024-53727-y","article-title":"Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial","volume":"15","author":"LN Carpp","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"pmed.1005230.ref012","article-title":"Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons","volume":"17","author":"PL Tzou","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"pmed.1005230.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"D Bates","year":"2015","journal-title":"J Stat Softw"},{"issue":"11","key":"pmed.1005230.ref014","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00194-5","article-title":"Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis","volume":"4","author":"E Stadler","year":"2023","journal-title":"Lancet Microbe"},{"issue":"5","key":"pmed.1005230.ref015","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/archpediatrics.2009.31","article-title":"The relative merits of risk ratios and odds ratios","volume":"163","author":"P Cummings","year":"2009","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"3","key":"pmed.1005230.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses in R with the metafor Package","volume":"36","author":"W Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"pmed.1005230.ref017","author":"K Barto\u0144","year":"2025","journal-title":"MuMIn: Multi-Model Inference"},{"issue":"1","key":"pmed.1005230.ref018","article-title":"Rate and risk factors for severe\/critical disease among fully vaccinated persons with breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a high-risk national population","volume":"75","author":"AA Butt","year":"2022","journal-title":"Clin Infect Dis"},{"key":"pmed.1005230.ref019","doi-asserted-by":"crossref","first-page":"796807","DOI":"10.3389\/fmicb.2021.796807","article-title":"SARS-CoV-2 vaccination and protection against clinical disease: a retrospective study, Bouches-du-Rh\u00f4ne District, Southern France, 2021","volume":"12","author":"PE Fournier","year":"2021","journal-title":"Front Microbiol"},{"key":"pmed.1005230.ref020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijid.2022.01.030","article-title":"Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China","volume":"116","author":"Z Hu","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"13","key":"pmed.1005230.ref021","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.vaccine.2022.02.039","article-title":"Impact of the Sinopharm\u2019s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)","volume":"40","author":"F Ismail AlHosani","year":"2022","journal-title":"Vaccine"},{"issue":"6","key":"pmed.1005230.ref022","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/healthcare10061085","article-title":"Risk of SARS-CoV-2 infection breakthrough among the non-vaccinated and vaccinated population in Italy: a real-world evidence study based on big data","volume":"10","author":"A Perrella","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"4","key":"pmed.1005230.ref023","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5694\/mja2.52019","article-title":"The effectiveness of vaccination for preventing hospitalisation with COVID-19 in regional Queensland: a data linkage study","volume":"219","author":"NR Smoll","year":"2023","journal-title":"Med J Aust"},{"key":"pmed.1005230.ref024","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1265\/ehpm.22-00199","article-title":"Association between vaccination status and COVID-19-related health outcomes among community-dwelling COVID-19 patients in Nara, Japan","volume":"28","author":"K Tomioka","year":"2023","journal-title":"Environ Health Prev Med"},{"key":"pmed.1005230.ref025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijid.2021.12.321","article-title":"No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway","volume":"115","author":"L Veneti","year":"2022","journal-title":"Int J Infect Dis"},{"key":"pmed.1005230.ref026","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1265\/ehpm.23-00061","article-title":"Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1\/BA.2 and BA.5-predominant periods in Japan","volume":"28","author":"K Tomioka","year":"2023","journal-title":"Environ Health Prev Med"},{"key":"pmed.1005230.ref027","doi-asserted-by":"crossref","first-page":"1049393","DOI":"10.3389\/fimmu.2023.1049393","article-title":"Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks","volume":"14","author":"M Albreiki","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"pmed.1005230.ref028","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1473-3099(22)00154-2","article-title":"Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study","volume":"22","author":"P Bager","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"pmed.1005230.ref029","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074521","article-title":"Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study","volume":"381","author":"AS Bohnert","year":"2023","journal-title":"BMJ"},{"issue":"2","key":"pmed.1005230.ref030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamainternmed.2021.7949","article-title":"Severity of illness in persons infected with the SARS-CoV-2 delta variant vs beta variant in Qatar","volume":"182","author":"AA Butt","year":"2022","journal-title":"JAMA Intern Med"},{"key":"pmed.1005230.ref031","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijid.2022.11.024","article-title":"Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa","volume":"127","author":"M-A Davies","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pmed.1005230.ref032","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13062","article-title":"Comparative hospitalization risk for SARS-CoV-2 omicron and delta variant infections, by variant predominance periods and patient-level sequencing results, New York City, August 2021-January 2022","volume":"17","author":"SK Greene","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"pmed.1005230.ref033","doi-asserted-by":"crossref","first-page":"85","DOI":"10.21149\/15125","article-title":"The omicron wave in Mexico: vaccine protection against progression to severe Covid-19 in SARS-CoV-2-infected workers","volume":"66","author":"M Hern\u00e1ndez-\u00c1vila","year":"2023","journal-title":"Salud Publica Mex"},{"issue":"9","key":"pmed.1005230.ref034","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-022-01887-z","article-title":"Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1\/BA.1.1 or BA.2 subvariant infection in Southern California","volume":"28","author":"JA Lewnard","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"pmed.1005230.ref035","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1038\/s41467-022-31402-4","article-title":"COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods","volume":"13","author":"FB Mayr","year":"2022","journal-title":"Nat Commun"},{"issue":"10332","key":"pmed.1005230.ref036","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study","volume":"399","author":"T Nyberg","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"pmed.1005230.ref037","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-7568(22)00166-0","article-title":"COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study","volume":"3","author":"F Tang","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"4","key":"pmed.1005230.ref038","article-title":"Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population","volume":"19","author":"SNT Pool","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"pmed.1005230.ref039","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.eimc.2022.11.003","article-title":"Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination","volume":"42","author":"E Varea-Jim\u00e9nez","year":"2024","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"issue":"4","key":"pmed.1005230.ref040","doi-asserted-by":"crossref","first-page":"2200077","DOI":"10.2807\/1560-7917.ES.2022.27.4.2200077","article-title":"Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022","volume":"27","author":"L Veneti","year":"2022","journal-title":"Euro Surveill"},{"issue":"2","key":"pmed.1005230.ref041","article-title":"Estimation of vaccine effectiveness of coronaVac and BNT162b2 against severe outcomes over time among patients with SARS-CoV-2 omicron","volume":"6","author":"Y Wei","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"pmed.1005230.ref042","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jinf.2023.08.005","article-title":"COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study","volume":"87","author":"HJ Whitaker","year":"2023","journal-title":"J Infect"},{"key":"pmed.1005230.ref043","article-title":"What level of neutralising antibody protects from COVID-19?","author":"DS Khoury","year":"2021","journal-title":"medRxiv"},{"issue":"7","key":"pmed.1005230.ref044","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"SA Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"pmed.1005230.ref045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17476348.2023.2208349","article-title":"Convalescent plasma therapy in COVID-19: unravelling the data using the principles of antibody therapy","volume":"17","author":"A Casadevall","year":"2023","journal-title":"Expert Rev Respir Med"},{"issue":"10","key":"pmed.1005230.ref046","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"H Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"7","key":"pmed.1005230.ref047","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1473-3099(24)00804-1","article-title":"Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial","volume":"25","author":"G Haidar","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"23","key":"pmed.1005230.ref048","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19","volume":"386","author":"MJ Levin","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"pmed.1005230.ref049","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac625","article-title":"Association between AZD7442 (Tixagevimab-Cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality","volume":"76","author":"J Kertes","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pmed.1005230.ref050","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/cid\/ciac855","article-title":"Effectiveness of evusheld in immunocompromised patients: propensity score-matched analysis","volume":"76","author":"R Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pmed.1005230.ref051","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40264-024-01450-4","article-title":"Real-world effectiveness and safety of tixagevimab-cilgavimab: a target trial emulation study","volume":"47","author":"VKC Yan","year":"2024","journal-title":"Drug Saf"},{"issue":"473","key":"pmed.1005230.ref052","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1198\/016214505000000970","article-title":"Causal vaccine effects on binary postinfection outcomes","volume":"101","author":"MG Hudgens","year":"2006","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"pmed.1005230.ref053","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3201\/eid2902.221422","article-title":"Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection","volume":"29","author":"DS Khoury","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"pmed.1005230.ref054","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41541-023-00630-0","article-title":"Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine","volume":"8","author":"D Benkeser","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"1","key":"pmed.1005230.ref055","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41467-022-35768-3","article-title":"Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial","volume":"14","author":"Y Fong","year":"2023","journal-title":"Nat Commun"},{"issue":"12","key":"pmed.1005230.ref056","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","article-title":"Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial","volume":"7","author":"Y Fong","year":"2022","journal-title":"Nat Microbiol"},{"issue":"1","key":"pmed.1005230.ref057","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"D Cromer","year":"2022","journal-title":"Lancet Microbe"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:43:36Z","timestamp":1788374616000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005230"}},"subtitle":[],"editor":[{"given":"Simon","family":"Cauchemez","sequence":"first","affiliation":[{"name":"Institut Pasteur","place":["FRANCE"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1005230","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}